LPAQTL
MCID: LPP008
MIFTS: 67

Lipoprotein Quantitative Trait Locus (LPAQTL)

Categories: Cardiovascular diseases, Genetic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lipoprotein Quantitative Trait Locus

MalaCards integrated aliases for Lipoprotein Quantitative Trait Locus:

Name: Lipoprotein Quantitative Trait Locus 57 28 36
Coronary Artery Disease 57 11 53 41 43 14 63 16 71
Coronary Artery Disease, Susceptibility to 57 28 5
Coronary Artery Anomaly 11 14 33
Myocardial Ischemia 43 16 71
Congenital Anomaly of Coronary Artery 11 33
Coronary Arteriosclerosis 11 71
Coronary Artery Disorder 28 5
Coronary Heart Disease 11 71
Coronary Disease 11 43
Congenital Malformations of Coronary Vessels 33
Congenital Anomaly of Coronary Arteries 33
Congenital Coronary Artery Malposition 33
Congenital Coronary Artery Deformity 33
Coronary Artery Anomaly, Congenital 11
Congenital Coronary Artery Disorder 33
Congenital Coronary Artery Anomaly 33
Malformation of Coronary Vessels 33
Coronary Artery Abnormality 11
Congenital Coronary Disease 33
Lpa Deficiency, Congenital 57
Abnormal Coronary Artery 33
Coronary Syndrome 14
Lpaqtl 57
Chd 11

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



Summaries for Lipoprotein Quantitative Trait Locus

MedlinePlus: 41 Coronary artery disease (CAD) is the most common type of heart disease. It is the leading cause of death in the United States in both men and women. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. Over time, CAD can also weaken the heart muscle and contribute to heart failure and arrhythmias. Heart failure means the heart can't pump blood well to the rest of the body. Arrhythmias are changes in the normal beating rhythm of the heart. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Lipoprotein Quantitative Trait Locus, also known as coronary artery disease, is related to heart disease and type 2 diabetes mellitus, and has symptoms including tremor, angina pectoris and chest pain. An important gene associated with Lipoprotein Quantitative Trait Locus is LPA (Lipoprotein(A)), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involvement in the immune response in sepsis. The drugs Amiodarone and Oxymetazoline have been mentioned in the context of this disorder. Affiliated tissues include heart, bone marrow and endothelial.

OMIM®: 57 Lipoprotein(a) is a macromolecular complex in human plasma which represents a quantitative genetic trait with a heritability of 0.7 or higher. Lipoprotein(a) is composed of an LDL-like particle in which apoB (107730) is covalently bound by a single disulfide bond to apolipoprotein(a). Apo(a) has been demonstrated to be the main determinant of the quantitative Lp(a) trait. Variation in the number of plasminogen (PLG)-like kringle (K) IV type 2 tandem repeats in the apo(a) gene is inversely correlated to Lp(a) plasma levels in all populations studied. Several polymorphisms in the Lp(a) gene have been found to affect the apo(a) concentration level (summary by Ogorelkova et al., 1999). (618807) (Updated 08-Dec-2022)

PubMed Health : 63 Coronary artery disease: Coronary artery disease (CAD, also called coronary heart disease, or CHD) is caused by the narrowing of the large blood vessels that supply the heart with oxygen. These are called coronary arteries. Arteries that have become extremely narrow can cause shortness of breath and chest pain during physical activity. If a coronary artery suddenly becomes completely blocked, it can result in a heart attack. CAD can also lead to other health problems like heart failure or heart rhythm problems. Various treatments can be used to reduce the symptoms and the risk of complications.

Disease Ontology: 11 An artery disease that is characterized by plaque building up along the inner walls of the arteries of the heart resulting in a narrowing of the arteries and a reduced blood supply to the cardiac muscles.

Related Diseases for Lipoprotein Quantitative Trait Locus

Diseases related to Lipoprotein Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1747)
# Related Disease Score Top Affiliating Genes
1 heart disease 34.2 MIR92B MIR208A MIR17 MIR140 MIR126 LPA
2 type 2 diabetes mellitus 33.4 WFDC21P SOCS1 MIR182 MIR17 MIR155 MIR145
3 diabetes mellitus 33.2 SOCS1 MIR17 MIR155 MIR145 MIR140 MIR126
4 myocardial infarction 33.1 MIR208A MIR17 MIR155 MIR145 MIR126 LPA
5 cerebrovascular disease 32.8 MIR17 MIR155 MIR145 MIR140 MIR126
6 hypertension, essential 32.8 MIR208A MIR17 MIR155 MIR145 MIR126 LPA
7 cardiovascular system disease 32.7 MIR208A MIR17 MIR155 MIR145 MIR140 MIR126
8 intermediate coronary syndrome 32.6 MIR17 MIR145 MIR126
9 body mass index quantitative trait locus 11 32.4 SOCS1 MIR17 MIR155 MIR140 MIR126 LPA
10 arteries, anomalies of 32.2 MIR208A MIR182 MIR17 MIR155 MIR145 MIR140
11 prostate cancer 31.9 SOCS1 MIR182 MIR17 MIR145 MIR126 IGF2-AS
12 peripheral artery disease 31.9 MIR17 MIR126 CDKN2B-AS1
13 lung cancer 31.9 SOCS1 MIR92B MIR182 MIR17 MIR155 MIR145
14 gastric cancer 31.8 SOCS1 MIR17 MIR145 MIR126 HOTTIP H19
15 heart valve disease 31.7 MIR92B MIR17 MIR140 MIR126
16 esophageal cancer 31.7 MIR182 MIR17 MIR145 MIR140 MIR126 H19
17 connective tissue disease 31.6 MIR92B MIR182 MIR17 MIR155 MIR145 MIR140
18 aortic valve disease 2 31.6 MIR17 MIR126 LPA
19 kidney cancer 31.6 MIR182 MIR17 MIR145 MIR126 H19 GAS5
20 hepatocellular carcinoma 31.6 SOCS1 MIR182 MIR17 MIR155 MIR145 MIR140
21 disease of mental health 31.5 MIR17 MIR155 MIR140 MIR126
22 carbohydrate metabolic disorder 31.5 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
23 leukemia, acute myeloid 31.5 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
24 retinal disease 31.4 MIR17 MIR155 MIR140 MIR126 CDKN2A
25 lung cancer susceptibility 3 31.4 MIR182 MIR17 MIR145 MIR140 MIR126 H19
26 gastrointestinal system disease 31.4 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
27 ovarian disease 31.4 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
28 melanoma 31.4 WFDC21P MIR182 MIR17 MIR140 H19 GAS5
29 aortic valve disease 1 31.4 MIR17 MIR126 LPA H19
30 leukemia, chronic myeloid 31.4 SOCS1 MIR17 MIR155 MIR140 MIR126 H19
31 lymphoma, non-hodgkin, familial 31.4 SOCS1 MIR17 MIR155 MIR145 MIR140 MIR126
32 prostate disease 31.3 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
33 aortic disease 31.3 MIR17 MIR145 MIR126
34 eye disease 31.3 MIR17 MIR155 MIR140 MIR126 CDKN2B CDKN2A
35 retinal vascular disease 31.3 MIR17 MIR140 MIR126
36 retinitis pigmentosa 31.3 MIR182 MIR17 MIR145 MIR140 HOTTIP GAS5
37 osteogenic sarcoma 31.3 MIR140 HOTTIP H19 GAS5 CDKN2B-AS1 CDKN2A
38 b-cell lymphoma 31.3 SOCS1 MIR17 GAS5 CDKN2B CDKN2A
39 renal cell carcinoma, nonpapillary 31.2 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
40 peripheral nervous system disease 31.2 MIR17 MIR145 MIR140 MIR126 CDKN2A
41 esophageal disease 31.2 MIR182 MIR17 MIR145 MIR140 MIR126
42 aortic aneurysm, familial abdominal, 1 31.2 MIR126 H19 CDKN2B-AS1
43 breast cancer 31.2 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
44 nasopharyngeal carcinoma 31.1 MIR17 MIR155 MIR145 MIR140 H19 GAS5
45 rectum cancer 31.1 MIR17 MIR145 MIR140 MIR126
46 cervical cancer 31.1 MIR17 MIR155 MIR140 H19 GAS5 CDKN2B-AS1
47 bladder cancer 31.1 MIR17 MIR145 H19 GAS5 CDKN2B-AS1 CDKN2B
48 retinitis pigmentosa 11 31.1 MIR182 MIR140 MIR126 GAS5 CDKN2B-AS1 CDKN2A
49 overnutrition 31.1 MIR17 MIR155 MIR140 MIR126
50 colonic disease 31.1 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126

Graphical network of the top 20 diseases related to Lipoprotein Quantitative Trait Locus:



Diseases related to Lipoprotein  Quantitative Trait Locus

Symptoms & Phenotypes for Lipoprotein Quantitative Trait Locus

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Cardiovascular Heart:
increased risk cardiovascular disease (elevated lp(a))

Endocrine Features:
increased risk diabetes mellitus, type 2 (decreased lp(a))

Cardiovascular Vascular:
increased risk aortic valve calcification (elevated lp(a))

Clinical features from OMIM®:

618807 (Updated 08-Dec-2022)

UMLS symptoms related to Lipoprotein Quantitative Trait Locus:


tremor; angina pectoris; chest pain; edema; equilibration disorder; other and unspecified angina pectoris; substernal pain

Drugs & Therapeutics for Lipoprotein Quantitative Trait Locus

PubMed Health treatment related to Lipoprotein Quantitative Trait Locus: 63

The main goals of treatment for CAD are to relieve symptoms and prevent complications. Medication can reduce the symptoms and restrictions in everyday life caused by stable angina . Beta blockers , calcium channel blockers and nitrates are used for this purpose. If that doesn't help, doctors often try to widen the narrowed coronary artery with a procedure using a cardiac catheter . If the arteries are severely narrowed, or if several blood vessels are affected, bypass surgery may be considered. This involves taking a blood vessel from elsewhere in the body and using it to redirect blood around the blocked coronary artery (bypassing it). There are things you can do on your own to help prevent complications like a heart attack or heart failure : eating a healthy diet and getting enough exercise are two examples. If you smoke, you could try to give it up. Also, there are a number of different medications that can prevent complications and increase life expectancy. These include the following: Low doses of acetylsalicylic acid (the drug in medicines like "Aspirin ") to prevent blood clots Statins to protect the blood vessels Beta blockers to reduce the strain on the heart (especially in people with heart failure or high blood pressure )

Drugs for Lipoprotein Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 739)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
2
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
3
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
4
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
5
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
6
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
7
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
8
Fenofibrate Approved Phase 4 49562-28-9 3339
9
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
10
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
11
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
12
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
13
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
14
Zolpidem Approved Phase 4 82626-48-0 5732
15
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
16
Promethazine Approved, Investigational Phase 4 60-87-7 4927
17
Tenecteplase Approved Phase 4 191588-94-0
18
Iodine Approved, Investigational Phase 4 7553-56-2 807
19
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
20
Pitavastatin Approved Phase 4 147511-69-1 5282452
21
Nitric Oxide Approved Phase 4 10102-43-9 145068
22
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
23
Dobutamine Approved Phase 4 34368-04-2 36811
24
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
25
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
26
Thrombin Approved, Investigational Phase 4
27
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
30
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
31
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
32
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
33
Acetaminophen Approved Phase 4 103-90-2 1983
34
Amlodipine Approved Phase 4 88150-42-9 2162
35
Eplerenone Approved Phase 4 107724-20-9 443872
36
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
37
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
38
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
39
Probucol Approved, Investigational Phase 4 23288-49-5 4912
40
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
41
Atenolol Approved Phase 4 29122-68-7 2249
42
Glyburide Approved Phase 4 10238-21-8 3488
43
Hydroxychloroquine Approved Phase 4 118-42-3 3652
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
46
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
47
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
48
Morphine Approved, Investigational Phase 4 57-27-2 5288826
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
50
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743

Interventional clinical trials:

(show top 50) (show all 6420)
# Name Status NCT ID Phase Drugs
1 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
2 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
3 A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease Unknown status NCT03008083 Phase 4 3 months DAPT;12 months DAPT
4 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
5 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
6 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
7 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
8 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
9 Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study Unknown status NCT03700645 Phase 4 Allopurinol
10 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
11 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
12 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
13 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
14 Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
15 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
16 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
17 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
18 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
19 The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
20 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
21 The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography: Single Center, Randomized, Open-label, Trial Unknown status NCT03552432 Phase 4 Alirocumab
22 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
23 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Trial Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
24 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
25 Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound Unknown status NCT03529253 Phase 4 Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily;Rosuvastatin calcium10mg
26 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
27 A Randomized, Double-Blind, Placebo-Controlled Trial for DaZhu Rhodiola Rosea Capsule in the Treatment of Coronary Artery Disease With Angina Pectoris Unknown status NCT03633890 Phase 4 DaZhu Rhodiola Rosea Capsule;DaZhu Rhodiola Rosea Simulation Capsule
28 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
29 Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial) Unknown status NCT02501616 Phase 4 Metformin;Dapagliflozin
30 Evaluation of the Strategy of "One-stop" Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease Unknown status NCT03563768 Phase 4
31 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
32 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
33 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
34 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
35 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
36 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
37 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
38 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
39 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
40 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
41 Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion? (COPE Study): Long-Term Follow-up Study Unknown status NCT00852215 Phase 4
42 Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
43 Randomized Comparison of Zotarolimus- and Everolimus-Eluting Stents for Coronary Treatment Unknown status NCT00768846 Phase 4
44 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
45 Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent Unknown status NCT00661206 Phase 4 Clopidogrel;Placebo
46 Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials Unknown status NCT04129008 Phase 4 Indobufen and aspirin mimetic;Aspirin and indobufen mimetic
47 Acute Cerebrovascular Events During Extracorporeal Circulation a Comparison of New Minimized Perfusion Circuit to Standard Cardiopulmonary Bypass Unknown status NCT00862160 Phase 4
48 Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole Unknown status NCT00808314 Phase 4 Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT;Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
49 "Impact of Cigarette Smoking on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With P2Y12 Inhibitors" - Trial COPTER - Unknown status NCT02026713 Phase 4
50 On-line 3-dimensional Optical Frequency Domain Imaging to Optimize Bifurcation Stenting Using UltiMaster Stent: OPTIMUM Study Unknown status NCT02972489 Phase 4

Search NIH Clinical Center for Lipoprotein Quantitative Trait Locus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


atorvastatin
Atorvastatin calcium
cerivastatin
Cerivastatin sodium
Cholestyramine Resin
Clofibrate
colesevelam
Colesevelam hydrochloride
Colestipol
Colestipol Hydrochloride
Dextrothyroxine
Dextrothyroxine Sodium
eptifibatide
Fenofibrate
Fish Liver Oils
fluvastatin
Fluvastatin sodium
Gemfibrozil
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Lovastatin
Pravastatin
Pravastatin Sodium
Probucol
rosuvastatin
Simvastatin
Sulfinpyrazone
tirofiban
TIROFIBAN HYDROCHLORIDE

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lipoprotein Quantitative Trait Locus cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lipoprotein Quantitative Trait Locus:
CD34+ stem cells for treatment of congestive heart failure
Embryonic/Adult Cultured Cells Related to Lipoprotein Quantitative Trait Locus:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120

Cochrane evidence based reviews: coronary artery disease

Genetic Tests for Lipoprotein Quantitative Trait Locus

Genetic tests related to Lipoprotein Quantitative Trait Locus:

# Genetic test Affiliating Genes
1 Coronary Artery Disorder 28
2 Coronary Artery Disease, Susceptibility to 28
3 Lipoprotein(a) Quantitative Trait Locus 28 LPA

Anatomical Context for Lipoprotein Quantitative Trait Locus

Organs/tissues related to Lipoprotein Quantitative Trait Locus:

MalaCards : Heart, Bone Marrow, Endothelial, Lung, Bone, Kidney, Liver

Publications for Lipoprotein Quantitative Trait Locus

Articles related to Lipoprotein Quantitative Trait Locus:

(show top 50) (show all 59412)
# Title Authors PMID Year
1
A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. 53 62 5
10591678 1999
2
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. 53 62 5
8675673 1995
3
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. 62 57
17569884 2007
4
The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. 53 5
12843189 2003
5
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. 62 5
8770857 1996
6
Haemostasis and fibrinolysis after regular high-intensity interval training in patients with coronary artery disease: a randomised controlled trial. 62 41
36428083 2022
7
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. 57
31865966 2019
8
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. 5
31358993 2019
9
HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. 5
28126521 2017
10
A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. 57
28444229 2017
11
Genetic associations with valvular calcification and aortic stenosis. 57
23388002 2013
12
Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. 62 46
21195052 2011
13
Paraoxonase-1 is a major determinant of clopidogrel efficacy. 5
21170047 2011
14
Circulating microRNAs in patients with coronary artery disease. 62 46
20595655 2010
15
Lipoprotein(a) and risk of type 2 diabetes. 57
20511445 2010
16
Gene expression profiling in whole blood of patients with coronary artery disease. 62 46
20528768 2010
17
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. 57
20032323 2009
18
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. 62 46
19371267 2009
19
Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. 57
18560444 2008
20
Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. 57
16840570 2006
21
A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). 57
15523644 2004
22
Paraoxonase 1 polymorphisms and survival. 5
15241482 2004
23
Assessing the function of genetic variants in candidate gene association studies. 5
15266341 2004
24
Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. 5
15240653 2004
25
G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. 5
14707024 2004
26
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. 5
14671192 2003
27
Lp(a) lipoprotein, vascular disease, and mortality in the elderly. 57
14645638 2003
28
Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. 5
12082503 2002
29
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. 5
11888590 2002
30
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 5
11918623 2002
31
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 5
11889198 2002
32
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. 5
11810302 2002
33
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 5
11788650 2002
34
Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. 57
11698280 2001
35
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 5
11335891 2001
36
Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. 57
11285247 2001
37
The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. 5
11238489 2001
38
The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. 5
10843189 2000
39
Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians. 57
10484779 1999
40
The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. 5
10430617 1999
41
Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. 5
10084586 1999
42
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 5
9661650 1998
43
Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. 57
9577282 1998
44
Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? 5
9443884 1998
45
The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. 5
9385372 1997
46
Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. 5
9215303 1997
47
Lipoprotein (a): its role in childhood thromboembolism. 57
9164807 1997
48
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 5
9011577 1997
49
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. 5
8647950 1996
50
Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. 57
8541836 1995

Variations for Lipoprotein Quantitative Trait Locus

ClinVar genetic disease variations for Lipoprotein Quantitative Trait Locus:

5 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CELA2A NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn) SNV Pathogenic
633592 rs1352544800 GRCh37: 1:15789885-15789885
GRCh38: 1:15463390-15463390
2 CELA2A NM_033440.3(CELA2A):c.253C>A (p.Leu85Met) SNV Pathogenic
633593 rs558493952 GRCh37: 1:15789253-15789253
GRCh38: 1:15462758-15462758
3 CELA2A NM_033440.3(CELA2A):c.639+1G>C SNV Pathogenic
633594 rs752331004 GRCh37: 1:15792640-15792640
GRCh38: 1:15466145-15466145
4 CELA2A NM_033440.3(CELA2A):c.209C>T (p.Thr70Met) SNV Pathogenic
633595 rs372947070 GRCh37: 1:15788135-15788135
GRCh38: 1:15461640-15461640
5 HS3ST1 NM_005114.4(HS3ST1):c.-108-6848A>G SNV Risk Factor
441163 rs16881446 GRCh37: 4:11408585-11408585
GRCh38: 4:11406961-11406961
6 PON1 NM_000446.7(PON1):c.575A>G (p.Gln192Arg) SNV Risk Factor
13735 rs662 GRCh37: 7:94937446-94937446
GRCh38: 7:95308134-95308134
7 PON1 NM_000446.7(PON1):c.163T>A (p.Leu55Met) SNV Risk Factor
13736 rs854560 GRCh37: 7:94946084-94946084
GRCh38: 7:95316772-95316772
8 IRS1 NM_005544.3(IRS1):c.2911G>A (p.Gly971Arg) SNV Risk Factor
29761 rs1801278 GRCh37: 2:227660544-227660544
GRCh38: 2:226795828-226795828
9 TERT, LOC110806263 NM_198253.2(TERT):c.-1382T>C SNV Uncertain Significance
375479 rs2735940 GRCh37: 5:1296486-1296486
GRCh38: 5:1296371-1296371
10 PRKAG2 NM_016203.4(PRKAG2):c.590C>G (p.Pro197Arg) SNV Uncertain Significance
374128 rs368637364 GRCh37: 7:151372600-151372600
GRCh38: 7:151675514-151675514
11 RNF213-AS1, RNF213 NM_001256071.3(RNF213):c.11659A>G (p.Lys3887Glu) SNV Uncertain Significance
523426 rs1555673862 GRCh37: 17:78337499-78337499
GRCh38: 17:80363699-80363699
12 SMAD3 NM_005902.4(SMAD3):c.533-478T>C SNV Benign
1272319 GRCh37: 15:67458639-67458639
GRCh38: 15:67166301-67166301
13 CETP NM_000078.3(CETP):c.1264G>A (p.Val422Ile) SNV Benign
17525 rs5882 GRCh37: 16:57016092-57016092
GRCh38: 16:56982180-56982180
14 CETP NM_000078.3(CETP):c.118+279G>A SNV Benign
1239762 GRCh37: 16:56996288-56996288
GRCh38: 16:56962376-56962376
15 SELE NM_000450.2(SELE):c.38-139T>C SNV Benign
1684529 GRCh37: 1:169702278-169702278
GRCh38: 1:169733137-169733137
16 SELE NM_000450.2(SELE):c.1723C>T (p.Leu575Phe) SNV Benign
1684530 GRCh37: 1:169695870-169695870
GRCh38: 1:169726729-169726729
17 MIA3 NM_198551.4(MIA3):c.3632-105A>G SNV Benign
1684531 GRCh37: 1:222823529-222823529
GRCh38: 1:222650187-222650187
18 LRP6 NM_002336.3(LRP6):c.1750C>T (p.His584Tyr) SNV Not Provided
684469 rs756283420 GRCh37: 12:12318025-12318025
GRCh38: 12:12165091-12165091

Copy number variations for Lipoprotein Quantitative Trait Locus from CNVD:

6 (show all 14)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13312 1 1 117600000 Copy number Coronary Disease
2 21785 1 161475204 161643863 Copy number FCGR2A Coronary artery disease
3 71425 12 69818942 132349534 Copy number Coronary artery disease
4 112708 17 40930407 78774742 Copy number Coronary artery disease
5 139335 2 179004449 242951149 Copy number Coronary artery disease
6 195353 5 150157836 180857866 Copy number Coronary artery disease
7 195373 5 150183562 180857866 Copy number Coronary artery disease
8 207392 6 155500000 161000000 Gain or loss LPA Coronary artery disease
9 207742 6 160872504 161007397 Copy number LPA Coronary Disease
10 207743 6 160872504 161007397 Copy number LPA Coronary Disease
11 210787 6 31416574 170899992 Copy number Coronary artery disease
12 211337 6 32582950 170899992 Copy number Coronary artery disease
13 211383 6 32609209 170899992 Copy number Coronary artery disease
14 250037 9 19900000 32800000 Copy number Coronary Disease

Expression for Lipoprotein Quantitative Trait Locus

Search GEO for disease gene expression data for Lipoprotein Quantitative Trait Locus.

Pathways for Lipoprotein Quantitative Trait Locus

Pathways related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.03 MIR17 MIR155 MIR145
2 10.59 MIR155 MIR145 MIR126

GO Terms for Lipoprotein Quantitative Trait Locus

Cellular components related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.36 MIR17 MIR155 MIR145 MIR140 MIR126 H19

Biological processes related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 9.83 MIR92B MIR208A MIR182 MIR17 MIR155 MIR145
2 negative regulation of osteoblast differentiation GO:0045668 9.54 MIR208A MIR17 MIR140
3 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.32 MIR208A MIR17
4 negative regulation of BMP secretion GO:2001285 9.26 MIR17 MIR140
5 negative regulation of vascular associated smooth muscle cell dedifferentiation GO:1905175 9.16 MIR182 MIR145
6 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.02 MIR208A MIR182 MIR17 MIR145 MIR126

Molecular functions related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 MIR92B MIR208A MIR17 MIR155 MIR145 MIR140
2 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR92B MIR208A MIR182 MIR17 MIR155 MIR145

Sources for Lipoprotein Quantitative Trait Locus

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....